Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Immucell Corp (ICCC)

In Vitro & In Vivo Diagnostic Substances

https://www.immucell.com

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.

56 EVERGREEN DR
PORTLAND, ME

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/10/1995

Market Cap

28,982,396

Shares Outstanding

7,750,000

Weighted SO

7,750,864

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

TRGNF --.--%

ACOGF --.--%

FENC --.--%

LIPO --.--%

ELYM --.--%

CYT --.--%

ANEB --.--%

HCWB --.--%

MNOV --.--%

Beta

0.5880

Last Div

0.0000

Range

3.5-5.64

Chg

0.0100

Avg Vol

9990

Mkt Cap

28982396

Exch

NASDAQ

Country

US

Phone

207 878 2770

DCF Diff

9.9023

DCF

-4.8109

Div Yield

0.0000

P/S

1.2480

EV Multiple

-23.5048

P/FV

1.2320

Div Yield %

0.0000

P/E

-7.1360

PEG

-1.0263

Payout

0.0000

Current Ratio

2.3686

Quick Ratio

0.7668

Cash Ratio

0.2906

DSO

31.0232

DIO

155.1548

Op Cycle

186.1781

DPO

9.3129

CCC

176.8652

Gross Margin

0.2605

Op Margin

-0.1668

Pretax Margin

-0.1742

Net Margin

-0.1744

Eff Tax Rate

-0.0012

ROA

-0.0967

ROE

-0.1635

ROCE

-0.1039

NI/EBT

1.0012

EBT/EBIT

1.0441

EBIT/Rev

-0.1668

Debt Ratio

0.2818

D/E

0.5028

LT Debt/Cap

0.2947

Total Debt/Cap

0.3346

Int Coverage

126.4305

CF/Debt

-0.0195

Equity Multi

1.7845

Rec Turnover

11.7654

Pay Turnover

39.1929

Inv Turnover

2.3525

FA Turnover

0.7516

Asset Turnover

0.5548

OCF/Share

-0.0295

FCF/Share

-0.1170

Cash/Share

0.1696

OCF/Sales

-0.0099

FCF/OCF

3.9624

CF Coverage

-0.0195

ST Coverage

-0.1156

CapEx Coverage

-0.3376

Div&CapEx Cov

-0.3376

P/BV

1.2320

P/B

1.2320

P/S

1.2480

P/E

-7.1360

P/FCF

-31.7269

P/OCF

-125.3454

P/CF

-125.3454

PEG

-1.0263

P/S

1.2480

EV Multiple

-23.5048

P/FV

1.2320

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 07, 12:15 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

Revenue Product Segmentation